Molecular subtyping of small cell lung cancer

Liang, Jie; Guan, Xiaojiao; Bao, Guangyao; Yao, Yao; Zhong, Xinwen

doi:10.1016/j.semcancer.2022.05.010

Cited by 22 publications

(23 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cells may have been generated by the de-differentiation of EMT cells and may function as stem cells ( 15 – 19 , 50 , 51 ). CSCs play critical roles in promoting the metastasis of tumor cells and developing drug resistance ( 76 – 80 ). HIV-1 gp120 and tat may promote the formation of CSCs within the HPV-16 infected neoplastic epithelia; these cells may accelerate the development of HPV-associated malignancy in vivo .…”

Section: Discussionmentioning

confidence: 99%

HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Background:Global cancer statistics for 2022 show that lung cancer remains the most prevalent malignancy in terms of incidence and mortality worldwide [1,2]. Based on the histopathological type, lung cancer can be divided into two major categories: small cell lung cancer and non-small cell lung cancer [3,4]. Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, and its 5-year survival rate is only 16% [5].…”

Section: Tumor Markersmentioning

confidence: 99%

Efficacy of Careolizumab combined with chemotherapy and astragalus polysaccharide(APS) in patients with intermediate to advanced NSCLC and effects on lymphocyte subsets, regulatory T cells and serum tumor markers

Dong

Wan

2023

Preprint

View full text Add to dashboard Cite

Objctive:To observe the recent efficacy of the combination group on patients with intermediate to advanced non-small cell lung cancer (NSCLC) and the effects on lymphocyte subsets, regulatory T cells, serum cytokeratin 19 fragment (CYFRA21-1), angiopoietin-2 (Ang-2), and vascular endothelial growth factor (VEGF). Methods:188 patients with intermediate to advanced NSCLC admitted to our hospital from August 2021 to April 2023 were selected, and the patients were simply randomly divided into a combination group and a control group. The control group was treated with chemotherapy regimen, and the combination group was treated with Carelizumab and astragalus polysaccharide on top of it. The recent efficacy, lymphocyte subsets (B, NK, CD3+,CD4+, CD4+/CD8+), regulatory T cells (CD4+Treg) , serum tumor markers CYFRA21-1, carcinoembryonic antigen (CEA), tumor antigen 125 (CA125), neurospecific enolase (NSE)] and angiogenic indexes (Ang-2, VEGF). Results:The total effective rate of recent clinical efficacy in the combined group after treatment was 69.15%, which was significantly higher than that in the control group (38.3%) (P<0.05). After treatment, the levels of B, NK, CD3+, CD4+ and CD4+/CD8+ were reduced in both groups, and the levels in the combined group were higher than those in the control group (P<0.05); the levels of CYFRA21-1, CEA, CA125 and NSE were reduced in both groups, and the levels in the combined group were significantly lower than those in the control group (P<0.05); the levels of Ang-2 and The levels of Ang-2 and VEGF were reduced in both groups, and the levels of Ang-2 and VEGF in the combined group were significantly lower than those in the control group (P<0.05). Progression-free survival was higher in the combination group than in the control group (95% CI, 1.468-4.278; Log-rank P < 0.0001; HR, 2.506). Conclusion: Carelizumab combined with chemotherapy and astragalus polysaccharide has definite near-term efficacy in patients with intermediate to advanced NSCLC, and can reduce the impact on immune function, prolong patients' progression-free survival, significantly improve serum tumor marker levels and play a certain inhibitory effect on angiogenesis.

show abstract

“…HPV genotyping was performed with polymerase chain reaction-based microarray analysis using an Anyplex II HPV HR Detection (Seegene, Seoul, South Korea), which detected the 28 HPV genotypes including types 6,11,16,18,26,31,33,35,39,40,42,43,44,45,51,52,53,54,56,58,59, 61, 66 68, 69, 70, 73, and 82. Briefly, 2 aliquots of 5 µl of extracted DNA were tested in each of the two 20 µl reaction mixtures with primer sets A and B, according to the manufacturer's instructions on the CFX96 real-time polymerase chain reaction system (Bio-Rad Laboratories).…”

Section: Hpv Genotypingmentioning

confidence: 99%

“…While the NE-high subtype is characterized by worse prognosis and chemosensitivity, the NE-low group shows a relatively favorable prognosis and increased immune cell infiltration, which results in sensitivity to immunotherapeutic agents. [13][14][15][16] Moreover, a recent consensus proposal suggested grouping SCLC into 4 distinct molecular subtypes defined by 4 key transcriptional regulators: achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), yes-associated protein 1 (YAP1), and POU class 2 homeobox 3 (POU2F3). [17][18][19] The ASCL1-dominant and NEUROD1dominant subtypes show high NE expression and poor prognosis.…”

mentioning

confidence: 99%

Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix

Kim,

Nam

et al. 2023

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Cervical small cell neuroendocrine carcinoma (CSCNEC) is a rare, aggressive type of cervical cancer. The treatment for CSCNEC follows the chemotherapeutic regimens used for small cell lung cancer (SCLC), with which it shares similar clinical and histologic features. For the first time, we applied neuroendocrine (NE) and SCLC molecular subtyping immunohistochemical markers [achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), POU class 2 homeobox 3 (POU2F3), and yes-associated protein 1] in 45 patients with CSCNEC. For the combined NE score, 51.1% of NE-high and 48.9% of NE-low subtypes were identified. The NE-high subtype tended to show worse progression-free survival and overall survival (OS) than the NE-low subtype (P=0.059 and P=0.07, respectively). Applying the SCLC molecular subtyping, 53.3% of cases were identified as NEUROD1-dominant, 17.8% as ASCL1-dominant, 13.3% as YAP-dominant, and 4.4% as POU2F3-dominant, while 11.1% of cases showed negative expression for all markers; the distribution was different from that of SCLC. The NEUROD1-dominant subtype exhibited the worst OS, while the POU2F3 subtype exhibited the best OS (P=0.003), similar to SCLC. In addition, the ASCL1-dominant and NEUROD1-dominant subtypes showed high NE scores, while yes-associated protein 1-dominant and POU2F3-dominant subtypes showed low NE scores (P=0.008). In multivariate analysis, the NEUROD1 expression was further identified as the independent prognostic factor for worse OS, together with the high FIGO stage. CSCNEC was revealed to be a heterogeneous disease with different biological phenotypes and to share some similarities and differences with SCLC. Regarding the ongoing development of tailored treatments based on biomarkers in SCLC, the application of biomarker-driven individualized therapy would improve clinical outcomes in patients with CSCNEC.

show abstract

Molecular subtyping of small cell lung cancer

Cited by 22 publications

References 71 publications

HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells

HIV-1 Proteins gp120 and Tat Promote Epithelial-Mesenchymal Transition and Invasiveness of HPV-Positive and HPV-Negative Neoplastic Genital and Oral Epithelial Cells

Efficacy of Careolizumab combined with chemotherapy and astragalus polysaccharide(APS) in patients with intermediate to advanced NSCLC and effects on lymphocyte subsets, regulatory T cells and serum tumor markers

Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix

Contact Info

Product

Resources

About